Active	Status	Sponsor type	Region	Phase	Filter
3 Active 6 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Careram (iguratimod) / Eisai, R-Pharm
NCT04928066: The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA	Completed	4	100	RoW	Iguratimod, IGU, T-614, Tofacitinib, TF, Pred, Prednisone	Qilu Hospital of Shandong University	Arthritis, Rheumatoid	06/23	07/23
NCT05626348: The Clinical Efficacy of Immunomodulators in RA Patients	Recruiting	4	400	RoW	Iguratimod, IGU, T-614, Methotrexate, MTX, Adalimumab Injection, adalimu, Leflunomide, LEF, Hydroxychloroquine, HCQ	Qilu Hospital of Shandong University	Arthritis, Rheumatoid	06/25	12/26
NCT03855007: The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment	Completed	4	400	RoW	Iguratimod, T-614, MTX, methotrexate, HCQ, Hydroxychloroquine, Pred, Prednisone	Qilu Hospital of Shandong University	Arthritis, Rheumatoid	09/23	10/23